The takeaway
Adaptive Biotechnologies Corp shows a pronounced seasonal pattern over 7 years of data — strongest in June (+13.2%) and softest in April (−10.3%).
Right now
In July, the stock has risen 43% of years, averaging +2.7%, about +0.6 pts better than the S&P 500.
The full picture
Adaptive Biotechnologies Corp's most dependable month has been June, higher in 6 of 7 years; April has been its least reliable, up just 33% of the time.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Win rate % | ||||||||||||
| Median return % | ||||||||||||
| 2025 | ||||||||||||
| 2024 | ||||||||||||
| 2023 | ||||||||||||
| 2022 | ||||||||||||
| 2021 | ||||||||||||
| 2020 | ||||||||||||
| 2019 | — | — | — | — | — |
Month by month
The stock's clearest edge over the S&P 500 lands in June (+13.0 pts); it has trailed the market most in April (−11.9 pts).
“vs S&P” is Adaptive Biotechnologies Corp’s average for a month minus the S&P 500’s average for that same month — isolating Adaptive Biotechnologies Corp’s own seasonal edge from broad market drift.
Reality check
Over the last 5 years, June has closed higher 80% of the time versus 86% across the last 7 years — the pattern is holding.
Figures are the typical (median) June return and how often it rose — the last 5 years versus the last 7(the heatmap’s default window). This verdict stays anchored to that 7-year window even if you zoom the chart, so it never disagrees with the badges above.
In plain English
Strip the year back and a single month does the heavy lifting: June, up in 6 of 7 Junes while the other eleven tend to blur together.
Its average (+13.2%) and median (+11.5%) land within a hair of each other — the tell of steady, year-after-year gains rather than one outlier doing the work. It is also the calendar's calmest month, its returns swinging least from year to year (a 9.1% spread), and even its worst June in 7 years lost only 4.8% — the gentlest downside anywhere on its calendar. Crucially, the gain is the stock's own rather than a rising tide's: June has cleared the S&P 500 by +13.0 points above the index. That consistency sets it apart from the field, where the average stock manages June only about 52% of the time.
No other month comes close to matching it — the rest of the calendar is unremarkable by comparison. The weaker half of the year is plainer: April has been the soft spot — the weakest of 6 months that average a loss (−10.3%), and the edge isn't year-round — the stock has trailed the S&P 500 in April, March, and September. Its roughest month on record was a −44.0% April in 2022 — a reminder of how hard even a seasonal name can fall.
Reassuringly, the tendency has held its shape: the recent five years still track the years behind them.
The takeaway is less about when to buy than what to expect: June aside, the stock's months offer little reliable tilt. With a short 7-year record and returns that swing hard year to year, the signal is best held loosely.
Short answers on the stock's best month (June), its worst (April), and whether it really trades seasonally.
Yes, to a pronounced degree. Since 2019 its best month (June, +13.2%) has run well ahead of its worst (April, −10.3%) — the heatmap above shows how steady that gap has been year to year.
June has been the strongest, averaging +13.2% and closing higher in 6 of 7 years since 2019.
It's the weakest, averaging −10.3% — historically a soft spot, though it still varies from year to year.
Explore
These names have the strongest July track records on record — a starting point for comparison.
Before you trade